Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Emicizumab, a bispecific monoclonal antibody, bridges activated factor IX (FIXa) and FX, replacing the function of missing FVIIIa to restore effective hemostasis in persons with hemophilia A (PwHA). Here we assess pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers in PwHA with FVIII inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitt, Christophe, Adamkewicz, Joanne I., Xu, Jin, Petry, Claire, Catalani, Olivier, Young, Guy, Negrier, Claude, Callaghan, Michael U., Levy, Gallia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895541/
https://www.ncbi.nlm.nih.gov/pubmed/33086400
http://dx.doi.org/10.1055/s-0040-1717114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895541/
https://www.ncbi.nlm.nih.gov/pubmed/33086400
http://dx.doi.org/10.1055/s-0040-1717114

Ejemplares similares